Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study

ConclusionsPatients treated with apremilast for 6 months in Italian clinical practice reported improved QoL, clinically relevant improvements in symptoms, high treatment satisfaction, and high treatment persistence. Our data indicate apremilast is a valuable treatment option for moderate plaque psoriasis.Study RegistrationClinicalTrials.gov identifier, NCT04031027.

http://link.springer.com/10.1007/s12325-023-02516-y

Source: Advances in Therapy - May 12, 2023 Category: Drugs & Pharmacology Source Type: research